Product Details
NUCALA 100MG 1ML SDV EA
Manufacturer: Glaxo Smith Kline
MFG#: 00173-0881-01
NDC: 00173-0881-01
PID: 666376
Additional Information
| Product Name | Nucala 100 Mg 1ml SDV Ea |
| Application | Interleukin-5 (IL-5) Antagonist |
| Generic Drug Name | Mepolizumab |
| Mechanism of Action | Inhibits IL-5, reducing eosinophil activation and inflammation |
| Strength | 100 mg |
| Dosage Form | Injection |
| Type | Subcutaneous |
| Administration Schedule | 100 mg subcutaneously every 4 weeks |
| Common Side Effects | Headache, injection site reactions, fatigue, back pain |
| Serious Reactions | Anaphylaxis, hypersensitivity reactions, increased infection risk |
| Precautions | Monitor for hypersensitivity reactions and parasitic infections |
| Storage Requirements | Requires Refrigeration (2°C to 8°C / 36°F to 46°F) |
| Container Type | Single-Dose Vial |
| Uses | Severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES) |
Description
Nucala (mepolizumab) is a monoclonal antibody that functions as an interleukin-5 (IL-5) antagonist. It is indicated as an add-on maintenance treatment for patients aged 6 years and older with severe eosinophilic asthma. By targeting IL-5, which plays a critical role in the growth, activation, and survival of eosinophils, Nucala helps reduce airway inflammation, thereby lowering the frequency of asthma exacerbations and improving respiratory function.
Nucala is approved for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA), a rare autoimmune condition characterized by eosinophilic inflammation and vasculitis. It is also indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) that has persisted for at least six months without an identifiable non-hematologic secondary cause.
Nucala is supplied as a sterile, lyophilized powder in a single-use vial containing 100 mg of mepolizumab. It requires reconstitution with sterile water before administration as a subcutaneous injection. The injection is typically given once every four weeks into the upper arm, thigh, or abdomen.
Frequently Asked Questions (FAQs)
The cost of NUCALA 100MG 1ML SDV EA is $available for registerd members only
NUCALA 100MG 1ML SDV EA is manufactured by Glaxo Smith Kline.
You can purchase NUCALA 100MG 1ML SDV EA on our website at https://supplies.pipelinemedical.com/product/detail/nucala-100mg-1ml-sdv-ea-666376